Chromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progression

3Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Medulloblastoma (MB), a common malignant pediatric brain tumor arising in the cerebellum, is characterized by mutations in chromatin modifiers, highlighting the significance of chromatin modification abnormalities in its progression. While animal models have effectively demonstrated this, a comprehensive evaluation of the oncogenic potential of these mutations remains incomplete. In this study, we use CRISPR-mediated gene editing to knock out chromatin modifier genes mutated in human SHH MB, along with the Ptch1 gene, in cerebellar granule neuron progenitors of neonatal mice. This reveals that depletion of Chd7 and Kmt2c accelerates tumor growth. Multi-layered omics analysis uncovers that inhibition of the neuronal differentiation program by chromatin dysregulation is a key signaling pathway in tumor progression. Additionally, forced expression of Neurod1, a common target of these chromatin modifiers, inhibits proliferation and promotes differentiation. These findings highlight converging chromatin modification abnormalities from distinct mutations in Sonic Hedgehog MB and suggest that epigenetic drugs activating neuronal genes have significant potential as novel treatments.

Cite

CITATION STYLE

APA

Wang, W., Kumegawa, K., Chapman, O. S., Shiraishi, R., Xiao, Z., Okonechnikov, K., … Kawauchi, D. (2025). Chromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progression. Cell Reports, 44(5). https://doi.org/10.1016/j.celrep.2025.115673

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free